Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparinoid sodium is a mixture of sulfated glycosaminoglycans (mucopolysaccharides) derived from animal tissues, structurally related to heparin. It is primarily employed in topical dermatological preparations for its anticoagulant, anti-inflammatory, and humectant properties. The drug exerts its therapeutic effects by inhibiting thrombin and Factor Xa, thereby improving microcirculation and reducing blood viscosity, and by inhibiting hyaluronidase to decrease tissue inflammation. Additionally, it enhances the water-holding capacity of the stratum corneum, making it effective for treating xeroderma (dry skin). It is also indicated for the management of hypertrophic scars, keloids, and superficial thrombophlebitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparinoid sodium.